Research presented at the ASCO Annual Meeting 2025 highlighted potential new standards of care and other advances in ...

Appendix cancer, once rare, is now rising sharply among younger people. Firstpost brings out an expert’s views on the risk ...

Recent advances in RAS-targeted therapies revolutionize treatment for gastrointestinal cancers, promising improved outcomes ...

Jenna Scott said doctors chalked up her abdominal cramping to pregnancy symptoms or IBS. It took a year to get diagnosed with ...

Appendix cancer is rare but it can still affect anyone The key is to stay vigilant watch out for early signs and take ...

Although cancer of the appendix is rare — typically, it's estimated to affect about 1 or 2 people for every 1 million in the ...

A rare gastrointestinal cancer is rising sharply among Gen X and Millennials, prompting experts to call for more research.

Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal ...

BE is the only known precursor to esophageal cancer. The condition is caused by prolonged exposure of the esophagus to ...

Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for ...

Two recent studies from Dr. Sita Kugel’s lab at Fred Hutch Cancer Center identify a key biological signature that not only ...